Payment overview · 2025
General Payments
$701.99
33 reported records · 18 companies
Healthcare provider profile · identity verified
Aaron Goodwin, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LENOIR, NC · NPI 1982014478
Verified facts
What the public records show
CMS Open Payments records show Aaron Goodwin, MD received $701.99 in general payments during 2025 across 33 reported records.
Insmed, Inc. accounted for 15.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Insmed, Inc. | Unresolved — no canonical attribution shown | $109.77 | 15.6% | 5 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $79.26 | 11.3% | 4 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $68.10 | 9.7% | 3 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $56.41 | 8.0% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $51.89 | 7.4% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $42.07 | 6.0% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $39.04 | 5.6% | 2 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.57 | 5.2% | 2 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $28.47 | 4.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $27.09 | 3.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $26.26 | 3.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $25.08 | 3.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.37 | 3.5% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $21.68 | 3.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.51 | 3.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.74 | 2.2% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $14.41 | 2.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.27 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $701.99 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $109.77 | 5 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $79.26 | 4 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $68.10 | 3 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $56.41 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $51.89 | 3 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $39.04 | 2 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $36.57 | 2 | 2025 |
Source payment records
|
|||||
| OPSYNVI Normalized: opsynvi |
Drug | Actelion Pharmaceuticals US, Inc. | $28.47 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $28.47 | 1 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $27.09 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $26.26 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $26.26 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $25.36 | 1 | 2025 |
Source payment records
|
|||||
| TAGRISSO Normalized: tagrisso |
Drug | AstraZeneca Pharmaceuticals LP | $25.08 | 1 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $24.37 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $23.38 | 1 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $21.68 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.51 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $21.51 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $16.71 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.74 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $14.41 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 69 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
65 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
69 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
141 | 41 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
127 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 477 | 129 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 473 | 140 |
| Atorvastatin Calcium | Atorvastatin Calcium | 471 | 128 |
| Amlodipine Besylate | Amlodipine Besylate | 465 | 134 |
| Pantoprazole Sodium | Pantoprazole Sodium | 433 | 124 |
| Omeprazole | Omeprazole | 272 | 85 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 259 | 74 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 256 | 68 |
| Lisinopril | Lisinopril | 236 | 67 |
| Gabapentin | Gabapentin | 224 | 74 |
| Carvedilol | Carvedilol | 193 | 54 |
| Metformin Hcl | Metformin Hcl | 185 | 50 |
| Metformin Hcl Er | Metformin Hcl | 185 | 58 |
| Losartan Potassium | Losartan Potassium | 175 | 49 |
| Furosemide | Furosemide | 168 | 68 |
| Tramadol Hcl | Tramadol Hcl | 165 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 162 | 56 |
| Famotidine | Famotidine | 156 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 152 | 50 |
| Potassium Chloride | Potassium Chloride | 151 | 47 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 145 | 48 |
| Prednisone | Prednisone | 142 | 80 |
| Alprazolam | Alprazolam | 141 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 141 | 44 |
| Ozempic | Semaglutide | 141 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 140 | 46 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 128 | 26 |
| Eliquis | Apixaban | 127 | 33 |
| Jardiance | Empagliflozin | 127 | 40 |
| Trazodone Hcl | Trazodone Hcl | 116 | 41 |
| Amitriptyline Hcl | Amitriptyline Hcl | 115 | 32 |
| Allopurinol | Allopurinol | 114 | 32 |
| Mounjaro | Tirzepatide | 113 | 19 |
| Lorazepam | Lorazepam | 107 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 105 | 30 |
| Ropinirole Hcl | Ropinirole Hcl | 101 | 29 |
| Doxycycline Hyclate | Doxycycline Hyclate | 94 | 71 |
| Metoprolol Tartrate | Metoprolol Tartrate | 93 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 92 | 37 |
| Sertraline Hcl | Sertraline Hcl | 92 | 26 |
| Montelukast Sodium | Montelukast Sodium | 91 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 89 | 26 |
| Terazosin Hcl | Terazosin Hcl | 87 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 84 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 81 | 20 |
| Alendronate Sodium | Alendronate Sodium | 79 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 78 | 28 |
| Meloxicam | Meloxicam | 78 | 21 |
| Spironolactone | Spironolactone | 78 | 24 |
| Fluconazole | Fluconazole | 73 | 38 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 73 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 71 | 56 |
| Buspirone Hcl | Buspirone Hcl | 69 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 69 | 11 |
| Bupropion Xl | Bupropion Hcl | 65 | 16 |
| Farxiga | Dapagliflozin Propanediol | 65 | 13 |
| Finasteride | Finasteride | 60 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 58 | 13 |
| Glipizide | Glipizide | 56 | 18 |
| Azelastine Hcl | Azelastine Hcl | 54 | 23 |
| Atenolol | Atenolol | 53 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 50 | 14 |
| Levetiracetam | Levetiracetam | 50 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | 15 |
| Cefuroxime | Cefuroxime Axetil | 49 | 31 |
| Colchicine | Colchicine | 47 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 47 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 44 | 14 |
| Irbesartan | Irbesartan | 42 | 13 |
| Promethazine Hcl | Promethazine Hcl | 42 | 14 |
| Solifenacin Succinate | Solifenacin Succinate | 42 | 16 |
| Klor-Con M20 | Potassium Chloride | 39 | 19 |
| Clonazepam | Clonazepam | 38 | suppressed |
| Topiramate | Topiramate | 38 | 12 |
| Estradiol | Estradiol | 36 | suppressed |
| Celecoxib | Celecoxib | 34 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | 11 |
| Donepezil Hcl | Donepezil Hcl | 34 | 15 |
| Glimepiride | Glimepiride | 34 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 34 | suppressed |
| Baclofen | Baclofen | 33 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 33 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | 17 |
| Pregabalin | Pregabalin | 32 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 31 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | suppressed |
| Azithromycin | Azithromycin | 30 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 30 | 11 |
| Glipizide Er | Glipizide | 29 | suppressed |
| Insulin Lispro | Insulin Lispro | 29 | suppressed |
| Lovastatin | Lovastatin | 29 | suppressed |
| Simvastatin | Simvastatin | 29 | suppressed |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 24 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | 11 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Risperidone | Risperidone | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Cilostazol | Cilostazol | 19 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Prolia | Denosumab | 19 | 12 |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Anastrozole | Anastrozole | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 12 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Testosterone | Testosterone | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Glassia | Alpha-1-Proteinase Inhibitor | 13 | suppressed |
| Ibu | Ibuprofen | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 12 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $701.99 · 33 records | Insmed, Inc. | Arikayce, Brinsupri, Cologuard Collection Kit, DUPIXENT, ETERNA, KEYTRUDA, Korlym, NUCALA, NURTEC ODT, OPSYNVI, Ohtuvayre, Omnipod, PURIFIED CORTROPHIN GEL, Prolastin-C Liquid, QULIPTA, TAGRISSO, TRELEGY ELLIPTA, Tyvaso, UBRELVY, UPTRAVI, Wegovy, YUPELRI, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error